<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520139</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 18-120 [HS# 2020-5846]</org_study_id>
    <secondary_id>2020-5846</secondary_id>
    <nct_id>NCT04520139</nct_id>
  </id_info>
  <brief_title>Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT</brief_title>
  <official_title>Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jarrow Formulas Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the&#xD;
      maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to&#xD;
      ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will&#xD;
      investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1 will be a dose-escalating design.&#xD;
Phase 2 will be a randomized, double-blinded, placebo-controlled study design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Phase 1 will be open label.&#xD;
Phase 2 will be be double-blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of N-Acetyl-Cysteine in Ovarian Cancer Patients Receiving Platinum-Based Therapy</measure>
    <time_frame>From the start date of treatment until 6 months after removal of treatment due to toxicity, termination of study or withdrawal of treatment, whichever came first.</time_frame>
    <description>Determination of the maximum tolerated dose (MTD) will be utilized to evaluate the safety and tolerability of adding N-Acetyl-Cysteine (NAC) in ovarian cancer patients who are also receiving platinum-based therapy (PBT), using a Phase I, dose-escalating design.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose for NAC administered with PBT</measure>
    <time_frame>From the start date of treatment until 6 months after removal of treatment due to toxicity, termination of study or withdrawal of treatment, whichever came first.</time_frame>
    <description>Determination of the recommended Phase 2 dose (RP2D) will be utilized to evaluate the safety and tolerability of adding NAC to PBT.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive NAC beginning at Cohort 1. If, at a given dose, none of the 3 patients shows a dose-limiting toxicity during the first cycle of PBT, then the dose is escalated 1 step for subsequent subjects. If, at a given dose, only 1 of 3 shows a dose-limiting toxicity, then up to 3 additional participants will be enrolled at that dose.If, at a given dose, the first 2, or any 2 of 3 subjects show a dose-limiting toxicity, then the dose will be de-escalated 1 step for future participants. At a dose where enrollment is expanded to between 4 and 6, if only 1 of 6 subjects shows a dose-limiting toxicity, then the dose will be escalated 1 step for future participants. However, if 2 or more of 4, 5, or 6participants show a dose-limiting toxicity, then the dose will be reduced one step for future participants. The maximum tolerated dose is defined as the highest dose not requiring deescalation. This is the dose to be used for the NAC arm of Phase II study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to receive NAC at the maximum tolerated dose or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetyl-Cysteine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Phase 1 Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
    <other_name>NAC Sustain</other_name>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Post-menopausal females (as defined by lack of menstruation for 12 months or status post&#xD;
        oophorectomy)&#xD;
&#xD;
          -  Histologic or pathologic diagnosis of stage III-IV epithelial ovarian, fallopian tube,&#xD;
             or primary peritoneal cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) â‰¤2&#xD;
&#xD;
          -  Life expectancy &gt; 1 year&#xD;
&#xD;
          -  Status post cytoreductive surgery for ovarian cancer or with planned cytoreductive&#xD;
             surgery if treated with neoadjuvant chemotherapy&#xD;
&#xD;
          -  Prescribed a minimum of six cycles of platinum-based chemotherapy&#xD;
&#xD;
          -  Adequate organ function as defined below:&#xD;
&#xD;
               1. Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
               2. Leukocytes &gt;1,500/mcl&#xD;
&#xD;
               3. Absolute Neutrophil Count &gt; 1,000/mcL&#xD;
&#xD;
               4. Platelets &gt; 125,00/mcL&#xD;
&#xD;
               5. total bilirubin Within normal institutional limits&#xD;
&#xD;
               6. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &lt; 2.5 x&#xD;
                  institutional upper limit of normal&#xD;
&#xD;
               7. Serum creatinine &lt; 1.5 mg/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of any cancer (other than non-melanoma skin cancer)&#xD;
&#xD;
          -  Chemotherapy, radiation therapy, or erythropoietin treatment within the last 6 months&#xD;
&#xD;
          -  Prior severe head injury&#xD;
&#xD;
          -  Has a history of dementia or other neurodegenerative disorders&#xD;
&#xD;
          -  Has an uncontrolled, treatment-resistant depression or other severe psychiatric&#xD;
             illnesses&#xD;
&#xD;
          -  Presence of known brain metastases&#xD;
&#xD;
          -  Has an active infection requiring treatment&#xD;
&#xD;
          -  Known immunosuppressive disease&#xD;
&#xD;
          -  Has active systemic autoimmune diseases such as lupus&#xD;
&#xD;
          -  Receipt of systemic immunosuppressive therapy&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C&#xD;
&#xD;
          -  Pregnant of breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study targets post-menopausal women with a histologically confirmed diagnosis of stage III-IV eipithelial ovarian cancer, fallopian tube, or primary peritoneal cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Bota, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chao Family Comprehensive Cancer Center University of California, Irvine</last_name>
    <phone>1-877-827-7883</phone>
    <email>ucstudy@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>University of California Irvine Medical</last_name>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Daniela A. Bota</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Chemotherapy-Related Cognitive Impairments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Chemotherapy-Related Cognitive Impairment</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

